Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 4/20 | 0.48 |
| ▸ | VEGFA | P15692 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17154894 | 0.90 | GBA1 (0.43) | OPRD1FAAHVEGFAEGLN1SPHK1 | |
| SCHEMBL16416167 | 0.85 | SPHK1 (0.47) | OPRD1FAAHVEGFAEGLN1SPHK1 | |
| SCHEMBL20945152 | 0.82 | SPHK2 (0.53) | SPHK1HDAC8HDAC6HDAC1 | |
| SCHEMBL24524824 | 0.80 | GBA1 (0.44) | — | |
| SCHEMBL25484823 | 0.80 | GBA1 (0.44) | — | |
| SCHEMBL23556843 | 0.80 | GBA1 (0.44) | — | |
| SCHEMBL24338282 | 0.80 | GBA1 (0.44) | — | |
| SCHEMBL24328 | 0.80 | SIGMAR1 (0.56) | — | |
| SCHEMBL7448432 | 0.80 | OPRD1 (0.56) | OPRD1FAAHVEGFAEGLN1HDAC8 | |
| SCHEMBL30339801 | 0.80 | OPRD1 (0.44) | OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2448926-A1 | FLAVIN DERIVATIVES | Biorelix, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011008247-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | OPRD1 3096/4885FAAH 1571/4885VEGFA 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.